source
- FDA schedules September advisory panel to review Grail's cancer test after trial missThe FDA announced it will hold an advisory committee meeting in September to examine Grail's multi‑cancer early detection test. The test recently failed to meet its primary endpoint in a large, ra…
- Ensoma cuts staff again to focus on lead gene therapy for rare immune diseaseBoston‑based biotech Ensoma announced another round of layoffs as it narrows its efforts to its sole clinical candidate, EN‑374, aimed at treating X‑linked chronic granulomatous disease (X‑CGD). E…